Introduction
Nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms and are opportunistic pathogens seen mostly in patients with impaired systemic immunity or in immunocompetent patients with chronic airway disease, such as COPD or cystic fibrosis (CF). The recognition of NTM as lung pathogens in immunocompetent hosts is often underappreciated as they cause insidious, subtle, and nonspecific symptoms (1) . This is especially true in CF patients with severe bronchiectasis whose airways are chronically infected with coexisting bacteria, that remarkably inhibit in vitro growth of NTM (2) (3) (4) . A recent large prospective multi-center study that applied vigilant screening and the use of appropriate NTM culture techniques showed that NTM are commonly isolated from the airway secretions of CF patients with an overall prevalence of 13% (5) . CF patients develop NTM diseases restricted to the lung (5, 7) whereas patients with advanced AIDS, develop disseminated NTM disease rarely involving the lung (8, 9) . This suggests complimentary roles of host local lung defense and systemic immune defense against NTM disease. NTM infections have been increasingly recognized after thoracic organ transplant (10, 11, (12) (13) (14) (15) (16) (17) (18) with the prevalence ranging from 1.4 to 6.5%. Cystic fibrosis is the leading indication for bilateral lung transplantations and comprised 31.5 % and 44 % of all adult and pediatric bilateral lung transplantations worldwide, respectively (19) . End-stage CF cohort serves as a unique, homogeneous group of high-risk lung transplant candidates in which to study the pre-transplant risk factors for the development of post-transplant NTM infection/disease. At the time of transplant surgery, the severe bronchiectatic airways harboring NTM are removed while systemic immunosuppressants are introduced. In addition, CF patients universally receive bilateral lung transplantation and thus, reduce the possibility of seeding NTM from native tissues (20) . CF lung transplant recipients undergo the abrupt transition from a population with local risk factors for NTM disease to a population with a combination of risk factor, including altered systemic immune status and inherited changes of the thorax after surgery.
In this retrospective study, we assessed the impact of pre-transplant NTM infection on the development of post-transplant NTM .
Methods

Patient Population
All CF patients who received lung transplantation at our institution (UNC) between January 1990 and May 2003 (n=146) and those awaiting lung transplant (May 2003) (n=31) were retrospectively studied. Institutional and referral medical records, microbiology, radiology and pathology databases, and lung transplant files were reviewed in accordance with the guidelines of the Institutional Committee on the Protection of the Rights of Human Subjects. The selection criteria, the operative techniques for the donors and recipients, and the post-lung transplant medical management have been previously published (11, 21, 22) .
Isolation and Identification of Nontuberculous Mycobacteria
Respiratory specimens from the lung transplant candidates, including sputa and bronchoalveolar lavage (BAL) fluids, were obtained at UNC from 1993 to May 2003 during routine transplant evaluation or, prior to that time, from the referral sites. Respiratory specimens from the lung transplant recipients (including sputa, bronchial wash, BAL fluids, lung tissue biopsies, and/or pleural fluids) and donors (bronchial washes at immediately post closure) were routinely processed and examined for the presence of NTM. Protocols for specimen processing, culture, and identification of NTM have been previously described (3) (4) (5) . Difficult-to-identify NTM were identified at the state reference laboratory. M. avium, M. intracellulare, and related strains were cumulatively reported as M. avium-complex.
NTM Isolation and Disease Definitions
Any positive NTM culture was considered an isolate regardless of AFB smear positivity. A negative isolation was defined as having at least two no-growth culture results. The disease caused by NTM was diagnosed according to the ATS Guidelines (23), which include constitutional symptoms, cough fever chills malaise, radiographic changes, such as new infilterates, nodules, bacteriological criteria, positive culture, with or without evidence of granulomatous inflammation in the lung tissue. CF clinicians made the decisions about NTM treatment and response before transplant following the best available literature at that time and the lung transplant physicians usually in consultation with the CF clinicians managed the post transplant NTM cases. Bronchiolitis obliterans syndrome (BOS) was diagnosed according to the ISHLT criteria (26) . Pulmonary function testing was performed as previously described (25) . After NTM disease was diagnosed, empirical broad-spectrum antibiotics were initiated based on the speciation according to ATS guidelines (23). The drug regimen was clarithromycin or azithromycin, cefoxitin and amikacin for mycobacterium abscessus, A quinolone was substituted for the amikacin in case of renal toxicity.A regimen of isoniazide , quinolone, rifabutin and ethambutol was used to treat M kansasii. No significant drug interactions or adverse events were noted.
Statistical Analyses
Non-normally distributed data were presented as medians and ranges or 95% confidence intervals. Student's t-test was performed on normally distributed data to determine if differences in baseline characteristics between end-stage CF patients who did and did not have NTM isolated pre-transplant were present. Nonparametric tests were used for non-normally distributed data. Fisher's exact test was used to analyze the association between the pre-transplant positive NTM isolation and the occurrence of NTM isolation and the development of NTM disease posttransplant
Results
Patient Population
One hundred seventy seven lung transplant candidates with end-stage CF, constituted the study cohort. One hundred and thirty-two of them (75%) had their respiratory specimens cultured for NTM prior to transplantation. For the remainder without NTM cultures, either the cultures were overgrown with bacteria, insufficient in quantity for processing, or were not obtained by the referring institution or UNC. The baseline characteristics of the 132 patients are shown in Table 1 , column A. They are representative of the entire population of CF lung-transplant candidates (n=177) and not different from those who did not have NTM cultures performed prior to transplantation (n=45). Twenty-six CF lung-transplant candidates cultured 29 NTM isolates from their respiratory specimens before transplantation (prevalence of 19.7 %) ( Figure 1 and Table 2 ). The characteristics of these 26 NTM-positive patients are shown in comparison to NTM-negative patients (n=106) in Table 1 . There were no differences in age, gender, %FVC, %FEV 1 , body mass index (BMI), or the coexistence of common bacterial pathogens in CF airway (Pseudomonas aeruginosa, Burkholderia cepacia complex, or Staphylococcus aureus) between the two groups (P > 0.2, each).
The most common NTM species isolated was M. avium-complex, n = 13 (45%), closely followed by M. abscessus, n = 12 (41%) ( Table 2 ). Other species recovered included M. gordonae, n = 2 (7%), M. fortuitum, n=1 (3%), and one isolate was unidentifiable, n = 1 (3%). .
Six patients had pre-transplant NTM disease, which was restricted to the lungs (patients 1, 2, 3, 8, 9, and 25; Table 2 ). All except one was due to M. abscessus. Four patients were successfully treated and 3 failed to improve after the treatment (patients 1, 3, and 9) and one was unable to tolerate the side effects of treatment (patient 2). The symptoms resolved quickly post treatment but one of the patients needed long term treatment due to recrudensence of infection when antibiotics were withdrawn.
Association between Pre-transplant NTM Isolation and Post-transplant NTM Isolation
None of the lung donors had a past medical history of NTM infection nor had they cultured NTM. Among pre-transplant NTM-positive patients who underwent transplantation (n=18, Figure 1 ; patients 1-18, Table 2 ), seven cultured NTM post-transplant (39%). In contrast, 10 of 89 (11 %) pretransplant NTM-negative had NTM isolation after transplant, but none developed NTM disease. There were no differences in any other characteristics, including age, gender, %FVC, %FEV 1 , BMI, or coexisting colonization of Pseudomonas spp or Burkholderia cepacia complex between pretransplant NTM-positive and NTM-negative transplant recipients (P > 0.5 each). Pre-transplant NTM-positive CF patients had 5.03 the odds of culturing NTM after lung transplant as compared to pre-transplant NTM-negative patients (P = 0.008, Table 4 ). Among seven pre-transplant NTMpositive patients who had NTM isolation after transplant (patients 1-7), five recultured the same species as they did pre-transplant {M. abscessus (n=2, patients 1 and 2); M. avium-complex (n=3, patients 3, 5, and 7); Table 2} . Table 2 ). The NTM were recovered between 1 to 101 months after transplant ( Table 2 ). The most common species isolated from transplanted lungs in CF patients were M. avium-complex, n = 9 (39 %), M. gordonae, n = 7 (30 %); and M. abscessus, n = 3 (13 %), followed by M. kansasii, n = 2 (9 %); M. szulgai (n=1) (4 %); and M. fortuitum (n=1) (4 %) ( Table 2 ).
NTM Isolates in CF Lung
There were no differences in pre-transplant characteristics, including recipient age, %FVC, %FEV 1 , BMI, or bacterial colonization in the airway between with NTM-positive and NTM-negative CF lung transplant recipients (P ≥ 0.2, for each characteristic, Table 3 ). The survival of NTM-positive CF recipients was not significantly different from NTM-negative recipients median 61 months (Range 11-111) (SD 33.5) versus median 44.7 (SD 39.5) months; P = 0.06). Definition of abbreviations: NTM = nontuberculous mycobacteria, BMI = body mass index.
NTM Disease After Lung Transplantation
With a mean post-transplant follow-up of 51.8 ± 35.6 months after the first isolate was identified, 5 of 20 NTM-positive recipients (25%) developed NTM disease (prevalence of 3.4% among all CF lung transplant recipients, Figure 1 ). Few NTM species caused disease after lung transplantation (Table 2) . M. abscessus (n = 3) and M. szulgai (n = 1). Only one of twelve M. avium-complex isolates that grew concurrent with M. szulgai and one of the two M. kansasii caused disease. In contrast, none of M. gordonae isolates (n=7) or of M. fortuitum isolates (n=1) caused disease ( Table  2 ). The disease onset ranged from 3 to 57 months after transplantation ( Table 2 ). The clinical and microbiological features of post-transplant NTM disease are summarized in Table 2 (n=5, patients 1, 2, 3, 7, and 39). Overall, the survival of CF lung recipients with post-transplant NTM disease (n=5) was not different from those without post-transplant NTM disease (n=141) (54.9 ± 27.4 months vs. 43.1 ± 37.2 months; P = 0.37).
Association between Pre-transplant NTM Isolation and Post-transplant NTM disease
Among pre-transplant NTM-positive recipients, four (22 %) developed disease (a mean follow-up of 34.0 ± 28.2 months after the first isolate was identified). In contrast, none of the pre-transplant NTM-negative patients who underwent transplantation (n=89) developed disease (Figure 1 ). The odds ratio for pre-transplant NTM-positive CF patients to develop NTM disease after lung transplant when comparing to pre-transplant NTM-negative patients was 6.13 (P = 0.001, Fisher's exact test; Table 4 ). Only pre-transplant M. abscessus-positive CF patients were more likely to develop posttransplant disease when compared to pre-transplant M. abscessus-negative patients (odds ratio = 7.45; P = 0.005, Fisher's exact test; Table 4 ). No significant association was found between pretransplant infection and post transplant disease with any other NTM species. After NTM disease was diagnosed, empirical antibiotic regimens were initiated based on the speciation according to ATS guidelines (25) .and the clinical details are summarized in Table 5 details are available on the online supplement. . 
Discussion
NTM were isolated among end-stage CF patients who were lung transplant candidates and, to a lesser extent, among CF lung transplant recipients, with prevalence rates of 19.7 % and 13.7 %, respectively. While post-transplant NTM disease caused significant morbidity in a small number of patients (prevalence of 3.4%), these patients were successfully treated; and the survival of patients with post-transplant NTM (isolation or disease) was not different from those without NTM.
The true prevalence of NTM among end-stage CF patients has not been previously determined. In this study, we report that approximately one in five end-stage CF patients awaiting lung transplant. Thus, NTM isolates are more prevalent among end-stage CF patients than among a more heterogeneous CF population evaluated in a much larger, prospective multi-center study (prevalence of ~13%; n = 986) (5). Observed in both studies, the two most common species isolated from CF airways were M. avium complex and M. abscessus.
Following lung transplantation, there have been only four previous case reports of NTM species isolated from their airways in CF recipients in the setting of either progressive graft dysfunction. Herein we reported 20 additional CF lung recipients with post-transplant pulmonary NTM isolates and confirmed the broad array of clinical settings in which the isolation of NTM can occur. Moreover, the 13.7 % prevalence rate of NTM isolates among our CF patients after transplant is two to three fold higher than that in the general (CF and non-CF) lung-transplant population (15, 16) indicated that CF patients are particularly prone to post-transplant NTM isolation. We found that the only pre-transplant predictor for post-transplant NTM isolation or disease was pre-transplant NTM isolation; the pre-transplant NTM-positive patients were at 5 times more likely to culture NTM species and 6 times more likely to develop NTM disease after lung transplant compared to pre-transplant NTM-negative patients. The similarity of NTM species recovered pre-and post-transplant, and the lack of their recovery from donor lungs in our study suggested that recurrence of NTM post-transplant was due to colonization of the native CF airway above the surgical anastomoses (i.e. main-stem bronchi, trachea or sinuses). The 2 patients with M. abscessus in their explanted (whole) hilar lymph nodes indicates that other reservoirs of NTM exist beyond the respiratory tract in CF patients and these may be potential sources of post-transplant infection if intraoperative contamination occurs.
Pulmonary (10-13, 15, 16, 18) and extra-pulmonary (15-17) diseases caused by NTMs have been increasingly recognized following thoracic organ transplantation. Without a consensus, the diagnosis of pulmonary NTM disease and differentiating it from colonization in immunocompromised lung-transplant patients represents an obstinate challenge. Often transplant pulmonologists treat isolates even if there is uncertainty of invasive disease. In this study, with a mean follow-up of 4 years after the recovery of the first isolate, only 5 of 146 CF lung recipients (3.4%) developed definite NTM disease, all of which involved the thorax. However 4 of the patients that had isolated NTM before transplant developed NTM disease after transplant (3 of the 4 were infected with M. abscessus). Only one patient (< 1%) developed disseminated disease. Thus, NTM isolation after transplant in individuals with CF is common, but rates of invasive disease are low.
Four cases of M. abscessus disease have been reported in general lung transplant recipients manifesting as empyema with (n=1) (28) or without (n=2) (15, 18) mycobacteremia, or graft dysfunction (n=1) (13) , resulting in death due to ventilatory failure (18, 26) . We extended these findings by confirming the particular virulence of, and the ability to recur after transplant by M. abscessus. Pre-transplant M. abscessus-culture positive CF patients, regardless of AFB smear positivity, were more likely to develop post-transplant disease when compared to pre-transplant M. abscessus-culture negative patients. Thus, a recurrent isolation of M. abscessus from a CF lung transplant recipient should increase the suspicion of the development of disease until proven otherwise. In addition, we observed two distinct presentations by M. abscessus after lung transplant, early infections that caused empyema or mediastinitis and late infection, in the setting of severe lung graft dysfunction (BOS stage 3), that caused lung abscess. In contrast to a previous report, we did not find that M. avium-complex was a common cause of post-transplant NTM disease (15) . In the only case of disease associated with M. avium-complex in our study, co-infection with M. szulgai, a known human pathogen (27) , may have been exclusively responsible for her deterioration.
These-data suggest that the high rate of NTM isolation in CF patients before transplant results in higher rates of NTM isolation after transplant, but does not increase the rate of NTM disease with the exception of M. abscessus. While treatment can be challenging all three cases of M. abscessus and one case of M. kansasii diseases were successfully treated. As a result, the survival of patients with post-transplant NTM isolation or disease was not different from those without. Proactive pre-transplant surveillance for NTM is advocated; the possible benefits from additional intra-operative NTM-specific antiseptic practices for these recipients remain unsettled.
This study has potential shortcomings. Retrospective studies can be limited by ascertainment bias despite our best efforts to review all available paper and electronic records. Second, we relied on microbiology results over a long time period and, thus, protocols for specimen processing, culture, and identification of NTM may have varied leading us to underestimate the number of cases of isolation and disease. Third, considerable controversy exists over the definitions of isolation, colonization, infection, and disease, which make it difficult to extrapolate from the non-CF literature and might confound our prevalence statistics. Nonetheless this is the largest study of NTM in CF patients referred for and following lung transplantation and our lengthy follow-up without the development of disease of the cases we defined as "NTM isolation" strengthened our conclusions. Fourth, as a single-center study, our study was limited by a relatively small number of NTM disease cases and practice changes over time may have affected the overall results. Last, we did not perform molecular genotyping studies to confirm that the cases of M abscessus that occurred early after transplant were true recurrences verses new acquisitions. Further study of the NTM in CF will be required before treatment recommendations can be made to address NTM-positive patients before lung transplant referral. In addition, comprehensive studies to assess potential post-transplant risk factors for NTM in both CF and non-CF patients are needed.
In conclusion, NTM are very commonly isolated from the airways of end-stage CF lungtransplant candidates. CF recipients are at increased risk for NTM isolation and NTM disease after lung transplant. However, the overall rates of invasive disease are low and the increased risk for post-transplant NTM disease is restricted largely to lung transplant candidates with pre-transplant M. abscessus isolates. Medical therapy effectively controls NTM disease after lung transplant resulting in no attributable mortality. The isolation of M abscessus pretransplant was associated with post transplant disease and morbidity but it did not affect survival. We recommend proactive transplant surveillance for M abscessus patiens and we await an outcomes analysis from other centers to confirm our findings and help us better understand the full impact of the mycobacterium abscessus on post transplant survival . Our findings support the isolation of mycobacterium abscessus from sputum to be a considered a relative, but not absolute, contraindication for transplant
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Figure 1.
Flow diagram representing the CF patients included in this study based on the presence of absence of NTM isolation pre-and post-transplant. 
